Crystal Arthropathies: Gout and Pseudogout - Acute and Chronic Management

Crystal arthropathies are inflammatory joint diseases caused by the deposition of crystals within synovial fluid and tissues. The two most clinically significant crystal arthropathies are gout (monosodium urate crystal deposition) and pseudogout (calcium pyrophosphate dihydrate crystal deposition, also known as chondrocalcinosis).

[KEY_CONCEPT] Gout is the most common inflammatory arthropathy in men over 40 years, affecting approximately 4% of the US population. It results from chronic hyperuricemia (serum uric acid >6.8 mg/dL), leading to supersaturation and precipitation of monosodium urate crystals in synovial fluid and tissues.

Pathophysiology of Gout:

• Uric acid production: End product of purine metabolism via xanthine oxidase
• Hyperuricemia mechanisms: Overproduction (10%) or underexcretion (90%)
• Crystal formation: Occurs when serum uric acid exceeds solubility threshold
• Inflammatory cascade: Crystals activate NLRP3 inflammasome, releasing IL-1β

[KEY_CONCEPT] Pseudogout (CPPD crystal arthropathy) involves calcium pyrophosphate dihydrate crystal deposition in fibrocartilage, particularly the knee menisci and triangular fibrocartilage complex of the wrist. Unlike gout, CPPD is primarily age-related, affecting >50% of individuals over age 85.

Risk Factors Comparison:

[CLINICAL_PEARL] Hyperuricemia alone is insufficient for gout diagnosis - many patients with elevated uric acid never develop clinical gout, while some acute attacks occur with normal serum levels.

Acute Gout Attack: The classic presentation involves sudden onset of severe, monoarticular joint pain, typically affecting the first metatarsophalangeal joint (podagra). The pain reaches maximum intensity within 6-12 hours and is often described as excruciating.

[HIGH_YIELD] Clinical Features of Acute Gout:

• Onset: Sudden, often nocturnal
• Location: First MTP (50%), ankle, knee, wrist
• Character: Severe, throbbing pain with exquisite tenderness
• Associated symptoms: Erythema, swelling, warmth, limited range of motion
• Triggers: Alcohol, purine-rich foods, dehydration, illness, surgery

Chronic Tophaceous Gout: Develops after years of recurrent attacks and inadequate uric acid control. Tophi are pathognomonic deposits of monosodium urate crystals surrounded by inflammatory tissue.

Common Tophi Locations:

• Helix and antihelix of ear
• Olecranon bursae
• Achilles tendons
• Finger joints and tendons
• Knees and ankles

Pseudogout (CPPD) Clinical Patterns:

[KEY_CONCEPT] CPPD manifests in several distinct clinical patterns:

1. Acute CPPD attacks: Mimic gout but typically affect larger joints (knee > wrist > ankle)
2. Chronic CPPD arthropathy: Progressive joint damage resembling osteoarthritis
3. Asymptomatic chondrocalcinosis: Cartilage calcification on imaging without symptoms

[CLINICAL_PEARL] The presence of chondrocalcinosis (cartilage calcification) on plain radiographs strongly suggests CPPD, especially when involving fibrocartilage structures like the knee menisci or triangular fibrocartilage complex of the wrist.

Gold Standard Diagnosis: [HIGH_YIELD] Synovial fluid analysis with polarized light microscopy remains the definitive diagnostic test for both gout and pseudogout.

Crystal Identification:

• Monosodium urate (gout): Needle-shaped, strongly negatively birefringent, yellow under parallel light
• CPPD (pseudogout): Rod or rhomboid-shaped, weakly positively birefringent, blue under parallel light

Diagnostic Criteria for Gout:

ACR/EULAR 2015 Gout Classification Criteria:

Step 1: ≥1 episode of swelling, pain, or tenderness in peripheral joint/bursa

Step 2: Presence of MSU crystals in symptomatic joint/bursa/tophus → If YES: Sufficient for classification as gout → If NO or not done: Continue to Step 3

Step 3: Clinical features (score ≥8 points needed): • Pattern of joint/bursa involvement: - 1st MTP involvement (2 points) - Ankle or midfoot involvement (1 point) • Characteristics of symptomatic episodes: - Erythema overlying joint (1 point) - Inability to tolerate touch/pressure (3 points) - Great difficulty walking/inability to use joint (2 points) • Time course: - Rapid onset (<24 hours to maximum pain) (2 points) - Resolution of symptoms in ≤14 days (1 point) • Clinical evidence of tophus (4 points) • Serum uric acid ≥6 mg/dL (3.5 points)

Laboratory Studies:

[KEY_CONCEPT] Serum uric acid levels during acute attacks may be normal or even low due to acute phase reaction. Measurement should be repeated 2-4 weeks after attack resolution.

Diagnostic Workup:

• Complete blood count: Leukocytosis during acute attacks
• ESR/CRP: Elevated during inflammation
• Comprehensive metabolic panel: Assess renal function, glucose
• Synovial fluid analysis: Cell count, crystals, culture
• 24-hour urine uric acid: If considering uricosuric therapy

Imaging Studies:

[CLINICAL_PEARL] Dual-energy CT (DECT) has excellent specificity (>95%) for detecting MSU crystal deposits and can identify subclinical tophi, but availability remains limited and cost is high.

Goals of Acute Treatment:

• Rapid pain relief and inflammation reduction
• Minimize attack duration and severity
• Avoid triggering factors that prolong symptoms

[HIGH_YIELD] First-Line Acute Therapies (start within 24 hours of symptom onset for optimal efficacy):

Treatment Algorithm for Acute Gout/Pseudogout:

Acute Crystal Arthropathy Attack ↓ Assess contraindications and comorbidities ↓ ┌─────────────┬─────────────┬─────────────┐ │ │ │ │ Colchicine NSAIDs Corticosteroids Combination │ │ │ Therapy │ │ │ │ Dose: 1.2mg Dose: Max Dose: Pred For severe then 0.6mg anti-inflam. 30-40mg/day or refractory in 1 hour doses for × 5-10 days attacks 5-10 days │ │ │ │ Monitor for Monitor renal Monitor blood Consider IL-1 diarrhea/ function, glucose, inhibitors if nausea GI bleeding mood changes available

1. Colchicine: [KEY_CONCEPT] Low-dose colchicine (1.2 mg followed by 0.6 mg one hour later) is as effective as high-dose regimens with significantly fewer side effects.

• Mechanism: Inhibits neutrophil chemotaxis and NLRP3 inflammasome
• Efficacy: Most effective when started <24 hours from onset
• Contraindications: Severe renal/hepatic impairment, concurrent strong CYP3A4/P-gp inhibitors

2. NSAIDs:

• First choice: Indomethacin 50mg TID, naproxen 750mg then 250mg TID
• Duration: Continue at full dose until symptoms resolve, then taper
• Contraindications: Active peptic ulcer disease, severe heart failure, advanced CKD

3. Corticosteroids: [CLINICAL_PEARL] Systemic corticosteroids are preferred in patients with contraindications to colchicine and NSAIDs, particularly those with heart failure, kidney disease, or multiple comorbidities.

• Oral: Prednisone 30-40mg daily × 5-10 days, then taper
• Intraarticular: Triamcinolone acetonide 10-40mg for monoarticular attacks
• Parenteral: Methylprednisolone 125mg IV/IM for hospitalized patients

Special Considerations:

• Chronic kidney disease: Avoid NSAIDs; reduce colchicine dose
• Heart failure: Prefer corticosteroids over NSAIDs
• Multiple attacks per year: Consider prophylactic therapy

Ineffective/Contraindicated:

• Aspirin (can precipitate attacks)
• Immediate uric acid-lowering therapy during acute attacks
• Opioids as monotherapy (inadequate anti-inflammatory effect)

Indications for Urate-Lowering Therapy (ULT):

[HIGH_YIELD] ACR Guidelines recommend ULT for:

• ≥2 gout attacks per year
• Presence of tophi
• Chronic kidney disease stage 3 or higher
• History of nephrolithiasis
• One attack in patient <40 years old

Target Serum Uric Acid:

• Standard target: <6.0 mg/dL (360 μmol/L)
• Tophaceous gout: <5.0 mg/dL (300 μmol/L) to promote tophus dissolution

Urate-Lowering Therapy Options:

ULT Initiation Strategy:

Patient meets criteria for ULT ↓ Start prophylaxis 2 weeks before ULT (Colchicine 0.6mg daily OR Low-dose prednisone) ↓ Initiate ULT at low dose during attack-free period ↓ Titrate ULT dose every 2-4 weeks based on serum uric acid ↓ Continue prophylaxis for 3-6 months after reaching target ↓ Monitor serum uric acid every 6 months once stable

[CLINICAL_PEARL] Prophylaxis during ULT initiation is crucial as rapid changes in serum uric acid can precipitate acute attacks. Continue prophylaxis for at least 3-6 months after reaching target uric acid levels.

Lifestyle Modifications:

• Dietary changes: Limit purine-rich foods (organ meats, certain seafood)
• Alcohol reduction: Especially beer and spirits
• Weight loss: If overweight/obese
• Hydration: Maintain adequate fluid intake
• Medication review: Avoid unnecessary diuretics, low-dose aspirin when possible

CPPD Management: [KEY_CONCEPT] No specific therapy exists to remove CPPD crystals or prevent chondrocalcinosis progression. Treatment focuses on:

• Acute attacks: Same as gout (colchicine, NSAIDs, corticosteroids)
• Chronic arthropathy: Symptomatic management similar to osteoarthritis
• Underlying conditions: Treat associated metabolic disorders (hyperparathyroidism, hemochromatosis)

Monitoring Parameters:

• Serum uric acid: Every 2-4 weeks during titration, then every 6 months
• Complete blood count: Baseline and periodically with allopurinol
• Liver function tests: Baseline and as clinically indicated
• Kidney function: Every 6-12 months, especially with uricosuric agents

Complications of Untreated Gout:

1. Chronic Tophaceous Gout:

• Development timeline: Typically after 10+ years of inadequate control
• Locations: Ears, joints, tendons, kidneys
• Consequences: Joint destruction, tendon rupture, functional impairment
• Reversibility: Tophi can dissolve with sustained uric acid <5.0 mg/dL

2. Gouty Nephropathy: [HIGH_YIELD] Three forms of kidney involvement:

• Chronic urate nephropathy: Progressive CKD from chronic hyperuricemia
• Acute uric acid nephropathy: Acute kidney injury from massive uric acid crystalluria
• Nephrolithiasis: Uric acid stones (radiolucent) in 10-25% of patients

3. Cardiovascular Complications: [KEY_CONCEPT] Gout is an independent risk factor for cardiovascular disease, likely due to chronic inflammation and associated comorbidities.

• Increased risk: Myocardial infarction, stroke, heart failure
• Mechanisms: Chronic inflammation, endothelial dysfunction
• Management: Aggressive cardiovascular risk modification

CPPD Complications:

• Progressive arthropathy: Resembles severe osteoarthritis
• Joint destruction: Particularly knees, wrists, shoulders
• Secondary osteoarthritis: Accelerated cartilage breakdown
• Spinal involvement: Crowned dens syndrome (atlantoaxial instability)

Prognosis and Outcomes:

Gout Prognosis:

[CLINICAL_PEARL] Long-term outcomes with appropriate ULT are excellent: Most patients achieve complete attack resolution and tophus dissolution when serum uric acid is maintained below target levels.

Treatment Response Markers:

• Attack frequency: Should decrease within 6-12 months of reaching target uric acid
• Tophus regression: Visible reduction within 6 months, complete resolution may take years
• Joint function: Improvement in range of motion and functional capacity
• Quality of life: Significant improvement in pain and disability scores

Factors Associated with Treatment Failure:

• Medication non-adherence: Most common cause of treatment failure
• Inadequate dosing: Not titrating ULT to achieve target uric acid
• Comorbid conditions: Advanced CKD, heart failure limiting treatment options
• Drug interactions: Medications that increase uric acid levels

[HIGH_YIELD] CPPD prognosis is generally less favorable than gout, as no effective therapy exists to prevent progression. Focus remains on symptomatic management and treating underlying metabolic conditions when identified.

Long-term Monitoring:

• Annual assessment: Attack frequency, functional status, medication adherence
• Imaging: Periodic assessment for joint damage progression
• Comorbidity management: Cardiovascular risk factors, kidney function
• Patient education: Ongoing reinforcement of lifestyle modifications